The Little Blue Book publisher rebrands, expands offering

Share this article:
The Little Blue Book publisher rebrands, expands offering
The Little Blue Book publisher rebrands, expands offering

A year after purchasing WebMD's The Little Blue Book, a referral directory for docs, mdHub changed its name to HCPlexus, and expanded its offerings to include, among other things, an iPad leasing program.

Physicians and other HCPs can now access The Little Blue Book (and its related products) without advertising, via paid subscription, or for free, with drug ads. According to David Shrier, HCPlexus's CEO, “a lot of physicians prefer to get ad-supported [content]. Our content philosophy is about choice.”

Shrier could not disclose download metrics for the mobile version of The Little Blue Book, which launched on August 3, but said he is “extremely gratified by the rapidity with which physicians and others have taken up mobile.” Regarding the iPad leasing program, a pharmaceutical marketer can underwrite the lease, and deliver an iPad preloaded with The Little Blue Book and other “essential reference tools” to physicians in practice, said Shrier.

Other new HCPlexus products include a formulary listing, and an online search function for The Little Blue Book (the latter will launch in October), according to Shrier. “We ask physicians what they want, and then go build it,” he said.

HCPlexus, a portmanteau comprising “HCP” and “plexus,” has sold programs into three of the top five pharmaceutical companies, and one of the top three pharmacy chains, said Shrier, adding that all new products "have metrics and measurability built in."

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...